{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:54:13Z","timestamp":1781844853092,"version":"3.54.5"},"reference-count":62,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Obtaining market approval and reimbursement are necessary but not sufficient conditions for the implementation of new vaccines in high-income countries to maximize their long-term preventative value. Comprehensive pre-launch and launch-phase economic evaluations of the disease and the vaccine are necessary to support long-term public health improvement by the vaccination program. This review highlights the construction of these evaluations conceived as a plan, methods, and a tool. They can be generated by different stakeholders (e.g., payers, producers, target groups) interested in the value success of vaccination. A Vaccine Launching Value Project (VLVP) has been developed based on the experience gained from helping to launch 10 new vaccines worldwide over 15 years (2005\u20132020). It comprises information on the following: (1) identification of new vaccines that should require a VLVP approach; (2) country-specific characteristics of healthcare; (3) methods to assess economic values for specific stakeholders; (4) identification of the money flow in managing the disease and infection spread; and (5) optimal implementation strategies at the initiation of new vaccination programs. The benefits of applying the VLVP are illustrated using rotavirus vaccination as an example. The VLVP program starts with the development of a Broad Country Linked Inventory (Brocoli) Plan that interconnects eight baskets of information specifying a framework of activities. This is followed by the Cauliflower and Artichoke Methods to assess the vaccine value for additional key stakeholders (e.g., employers, hospital managers, working mothers, the Ministry of Finance) and the money flow amongst the payers (who pays what to whom, when, for what, and how). The evaluation process finishes with the Total Management Tool (Tomato) to identify the optimal implementation conditions at the start of a new vaccination program necessary to obtain the best long-term value for the stakeholders selected. The critical interconnections between these information blocks are discussed. This improves the positioning of a new vaccine by articulating its total economic value within a societal and public health environment over time, outside the conventional Health Technology Assessment box. The Tomato Tool emerges as the most pivotal component of the VLVP. It provides the best assurance of long-term economic value with strong sustainability support.<\/jats:p>","DOI":"10.3390\/vaccines14060535","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T03:27:21Z","timestamp":1781666841000},"page":"535","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Proposed Conceptual and Experience-Based Framework for Reaching an Optimal Vaccine Launch Strategy"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6801-9654","authenticated-orcid":false,"given":"Baudouin","family":"Standaert","sequence":"first","affiliation":[{"name":"Department of Care and Ethics, Faculty of Medicine & Life Sciences, University of Hasselt, B-3590 Diepenbeek, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Raes","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Jessa Hospital, B-3500 Hasselt, Belgium"},{"name":"Department of Immunology & Infection, Faculty of Medicine & Life Sciences, University of Hasselt, B-3590 Diepenbeek, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"ref_1","unstructured":"Bianco, D., Milani, E., and Del Panta, I. (2024). The Value of Prevention for Economic Growth and the Sustainability of Healthcare, Social Care, and Welfare Systems, The European House\u2013Ambrosetti."},{"key":"ref_2","unstructured":"El Banhawi, H., Chowdhury, S., Neri, M., Radu, P., Besley, S., Bell, E., Brassel, S., and Steuten, L. (2024). The Socioeconomic Value of Adult Immunisation Programmes, Office of Health Economics."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"le Polain, M., Franken, M., Koopmanschap, M., and Cleemput, I. (2010). Drug Reimbursement Systems: International Comparsion and Policy Recommendations, Belgian Health Care Knowledge Centre (KCE). Contract No.: 147C.","DOI":"10.57598\/R147C"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Johns, A., Andrade, A., Johal, S., and Ryan, J. (2025). EU Joint Clinical Assessment: A Framework for Optimising Use with Cost-Effectiveness Decision-Making. J. Mark. Access Health Policy, 13.","DOI":"10.3390\/jmahp13040052"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1468-0009.2010.00598.x","article-title":"EBM, HTA, and CER: Clearing the confusion","volume":"88","author":"Luce","year":"2010","journal-title":"Milbank Q."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0168-8510(02)00059-3","article-title":"The development of health technology assessment","volume":"63","author":"Banta","year":"2003","journal-title":"Health Policy"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Cleemput, I., Neyt, M., Thiry, N., De Laet, C., and Leys, M. (2008). Threshold Values for Cost-Effectiveness in Health Care, KCE.","DOI":"10.57598\/R100C"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Moureau, N.L. (2019). Right Evaluation of Products and Compliance Measures. Vessel Health and Preservation: The Right Approach for Vascular Access, Springer International Publishing.","DOI":"10.1007\/978-3-030-03149-7"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2165\/00019053-199600093-00005","article-title":"Economic evaluation of vaccination","volume":"9","author":"Beutels","year":"1996","journal-title":"Pharmacoeconomics"},{"key":"ref_11","unstructured":"Hall, E., Wodi, P., Hamborsky, J., Morelli, V., and Schillie, S. (2024). Immunization strategies for healthcare practices and providers. Epidemiology and Prevention of Vaccine-Preventable Diseases, Public Health Foundation. Centers for Disease Control and Prevention."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.acap.2021.02.015","article-title":"Implementing Effective Vaccination Interventions Into Sustainable \u2018Real World\u2019 Practice","volume":"21","author":"Stockwell","year":"2021","journal-title":"Acad. Pediatr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"100519","DOI":"10.1016\/j.jvacx.2024.100519","article-title":"Strategies used to improve vaccine uptake among healthcare providers: A systematic review","volume":"19","author":"Spanaus","year":"2024","journal-title":"Vaccine X"},{"key":"ref_14","unstructured":"Russell, S., Harries, J., Hewitt, P., and Doyle, A. (2023). Shaping the Future Delivery of NHS Vaccination Services, NHS England. Contract No.: PR00339."},{"key":"ref_15","unstructured":"European Centre for Disease Prevention and Control (2025). Tools and Methods for Promoting Vaccination Acceptance and Uptake: A Social and Behavioural Science Approach, European Centre for Disease Prevention and Control. Contract No.: TQ-01-25-026-EN-N."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/S0140-6736(24)00850-X","article-title":"Contribution of vaccination to improved survival and health: Modelling 50 years of the Expanded Programme on Immunization","volume":"403","author":"Shattock","year":"2024","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Bishai, D., Brenzel, L., and Padula, W. (2023). Budget impact analysis and return on investment. Handbook of Applied Health Economics in Vaccines, Oxford University Press.","DOI":"10.1093\/oso\/9780192896087.001.0001"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.vaccine.2016.11.056","article-title":"Beyond expectations: Post-implementation data shows rotavirus vaccination is likely cost-saving in Australia","volume":"35","author":"Reyes","year":"2017","journal-title":"Vaccine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/S2214-109X(13)70170-0","article-title":"Reassessing the value of vaccines","volume":"2","author":"Berkley","year":"2014","journal-title":"Lancet Glob. Health"},{"key":"ref_20","unstructured":"World Health Organization (2025, November 22). Essential Programme on Immunisation. Available online: https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/essential-programme-on-immunization."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1377\/hlthaff.2011.0332","article-title":"An analysis of how the GAVI alliance and low- and middle-income countries can share costs of new vaccines","volume":"30","author":"Saxenian","year":"2011","journal-title":"Health Aff."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.vaccine.2022.11.037","article-title":"Sustainable financing for Immunization Agenda 2030","volume":"42","author":"Saxenian","year":"2024","journal-title":"Vaccine"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(07)61744-9","article-title":"Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: Randomised, double-blind controlled study","volume":"370","author":"Vesikari","year":"2007","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1336044","DOI":"10.1080\/20016689.2017.1336044","article-title":"3. How comprehensive can we be in the economic assessment of vaccines?","volume":"5","author":"Standaert","year":"2017","journal-title":"J. Mark. Access Health Policy"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"23897","DOI":"10.3402\/jmahp.v2.23897","article-title":"Is the gap between micro- and macroeconomic assessments in health care well understood? The case of vaccination and potential remedies","volume":"2","author":"Kotsopoulos","year":"2014","journal-title":"J. Mark. Access Health Policy"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Curtis, N.F.A., and Pollard, A. (2011). The Value of Vaccination. Hot Topics in Infection and Immunity in Children VII, Springer. Advances in Experimental Medicine and Biology; Contract No.: CC BY-NC-SA 3.0 IGO.","DOI":"10.1007\/978-1-4419-7185-2"},{"key":"ref_27","unstructured":"World Health Organization (2020). Global Vaccine Action Plan: Monitoring, Evaluation, and Accountability, WHO."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.fmre.2024.08.002","article-title":"Supply chain resilience: A review from the inventory management perspective","volume":"5","author":"Guo","year":"2025","journal-title":"Fundam. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/smj.192","article-title":"Resource-based strategy and managerial power in networks of internationally dispersed technology units","volume":"22","author":"Medcof","year":"2001","journal-title":"Strateg. Manag. J."},{"key":"ref_30","unstructured":"Berkley, S., Chan, M.C.Y., Elias, C., Fauci, A., Lake, A., and Phumaphi, J. (2013). Global Vaccine Action Plan, 2011\u20132020, World Health Organization (WHO)."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jval.2018.08.005","article-title":"Economic Analysis of Vaccination Programs: An ISPOR Good Practices for Outcomes Research Task Force Report","volume":"21","author":"Mauskopf","year":"2018","journal-title":"Value Health"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jval.2016.11.018","article-title":"The Fiscal Consequences Attributed to Changes in Morbidity and Mortality Linked to Investments in Health Care: A Government Perspective Analytic Framework","volume":"20","author":"Connolly","year":"2017","journal-title":"Value Health"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2509484","DOI":"10.1080\/21645515.2025.2509484","article-title":"Using the CARD system for university-based pop-up vaccination clinics: A two-stage hybrid effectiveness-implementation study","volume":"21","author":"Gudzak","year":"2025","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1097\/01.inf.0000197622.98559.01","article-title":"Burden of rotavirus disease in European Union countries","volume":"25","author":"Mrukowicz","year":"2006","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6255","DOI":"10.1016\/j.vaccine.2017.09.048","article-title":"Estimating the full public health value of vaccination","volume":"35","author":"Gessner","year":"2017","journal-title":"Vaccine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1719588","DOI":"10.1080\/20016689.2020.1719588","article-title":"How to assess for the full economic value of vaccines? From past to present, drawing lessons for the future","volume":"8","author":"Standaert","year":"2020","journal-title":"J. Mark. Access Health Policy"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2021.1875762","article-title":"Patient-reported outcomes in vaccines research: Relevance for decision-making","volume":"18","author":"Curran","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1080\/21645515.2015.1029212","article-title":"Improvement in hospital Quality of Care (QoC) after the introduction of rotavirus vaccination: An evaluation study in Belgium","volume":"11","author":"Standaert","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e007453","DOI":"10.1136\/bmjopen-2014-007453","article-title":"Exploring the potential impact of rotavirus vaccination on work absenteeism among female administrative personnel of the City of Antwerp through a retrospective database analysis","volume":"5","author":"Standaert","year":"2015","journal-title":"BMJ Open"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00431-007-0428-9","article-title":"Rotavirus gastroenteritis: Epidemiological data from a regional hospital in Belgium","volume":"167","author":"Raes","year":"2008","journal-title":"Eur. J. Pediatr."},{"key":"ref_41","first-page":"1399","article-title":"Claims-based Analysis of Zoster Vaccine Effectiveness against Incident Herpes Zoster: The VENUS Study","volume":"8","author":"Murata","year":"2025","journal-title":"JMA J."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Faust, H.S., and Menzel, P.T. (2012). Prevention vs. Treatment, What\u2019s the Right Balance?, Oxford University Press.","DOI":"10.1093\/acprof:oso\/9780199837373.001.0001"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1335162","DOI":"10.1080\/20016689.2017.1335162","article-title":"Towards a more comprehensive approach for a total economic assessment of vaccines?: 1. The building blocks for a health economic assessment of vaccination","volume":"5","author":"Standaert","year":"2017","journal-title":"J. Mark. Access Health Policy"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jval.2015.12.003","article-title":"Multiple Criteria Decision Analysis for Health Care Decision Making\u2014An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force","volume":"19","author":"Thokala","year":"2016","journal-title":"Value Health"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jval.2016.02.001","article-title":"Challenges in Using MCDA for Reimbursement Decisions on New Medicines?","volume":"19","author":"Walker","year":"2016","journal-title":"Value Health"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.1016\/j.vaccine.2018.08.001","article-title":"Preferences for vaccines against children\u2019s diarrheal illness among mothers in Poland and Hungary","volume":"36","author":"Poulos","year":"2018","journal-title":"Vaccine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.vhri.2019.11.001","article-title":"Applying a Constrained Optimization Portfolio Model to Aid Prioritization of Public Health Interventions in Malaysia","volume":"21","author":"Varghese","year":"2020","journal-title":"Value Health Reg. Issues"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1093\/infdis\/jiad188","article-title":"Burden of Respiratory Syncytial Virus in the European Union: Estimation of RSV-associated hospitalizations in children under 5 years","volume":"228","author":"Spreeuwenberg","year":"2023","journal-title":"J. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s40273-020-00978-4","article-title":"Comparing the Analysis and Results of a Modified Social Accounting Matrix Framework with Conventional Methods of Reporting Indirect Non-Medical Costs","volume":"39","author":"Standaert","year":"2021","journal-title":"Pharmacoeconomics"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5611","DOI":"10.1016\/j.vaccine.2017.08.052","article-title":"Impact of five years of rotavirus vaccination in Finland\u2014And the associated cost savings in secondary healthcare","volume":"35","author":"Leino","year":"2017","journal-title":"Vaccine"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.vaccine.2016.11.057","article-title":"Impact of the national rotavirus vaccination programme on acute gastroenteritis in England and associated costs averted","volume":"35","author":"Thomas","year":"2017","journal-title":"Vaccine"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Standaert, B., Raes, M., Ethgen, O., Benninghoff, B., and Toumi, M. (2024). Measuring the Vaccine Success Index: A Framework for Long-Term Economic Evaluation and Monitoring in the Case of Rotavirus Vaccination. Vaccines, 12.","DOI":"10.20944\/preprints202410.0772.v1"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"6671","DOI":"10.1016\/j.vaccine.2021.09.059","article-title":"Impact analysis of rotavirus vaccination in various geographic regions in Western Europe","volume":"39","author":"Verberk","year":"2021","journal-title":"Vaccine"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jval.2021.10.017","article-title":"Economic Evaluation of Vaccination Programs: A Guide for Selecting Modeling Approaches","volume":"25","author":"Mauskopf","year":"2022","journal-title":"Value Health"},{"key":"ref_55","unstructured":"European Centre for Disease Prevention and Control (2021). Partial COVID-19 Vaccination, Vaccination Following SARS-CoV_2 Infection and Heterologous Vaccination Schedule: Summary of Evidence, ECDC."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1016\/j.vaccine.2007.02.070","article-title":"Evaluating rotavirus vaccination in England and Wales: Part II. The potential cost-effectiveness of vaccination","volume":"25","author":"Jit","year":"2007","journal-title":"Vaccine"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.vaccine.2011.11.064","article-title":"Impact of rotavirus vaccination on epidemiological dynamics in England and Wales","volume":"30","author":"Atkins","year":"2012","journal-title":"Vaccine"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1017\/S0950268809991245","article-title":"A mathematical model of the indirect effects of rotavirus vaccination","volume":"138","author":"Debrus","year":"2010","journal-title":"Epidemiol. Infect."},{"key":"ref_59","unstructured":"Kucharski, A. (2020). A theory of happenings. The Rules of Contagion, Profile Books Ltd."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/eurpub\/ckae027","article-title":"From \u2018evidence-based\u2019 towards \u2018value-based\u2019 public health: Measuring what matters most","volume":"34","author":"Dyakova","year":"2024","journal-title":"Eur. J. Public Health"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1748-5908-2-11","article-title":"Using a summary measure for multiple quality indicators in primary care: The Summary QUality InDex (SQUID)","volume":"2","author":"Nietert","year":"2007","journal-title":"Implement. Sci."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Standaert, B., Topachevskyi, O., and Ethgen, O. (2025). Vaccine Development, Its Implementation and Price Setting: A Historical Perspective with Proposed Ways to Move Forward. J. Mark. Access Health Policy, 13.","DOI":"10.3390\/jmahp13040050"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/6\/535\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:46:43Z","timestamp":1781844403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/6\/535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":62,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["vaccines14060535"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14060535","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]}}}